EGFR mutations cause abnormal activation of the downstream JAK/STAT3 signalling pathway, leading to the expression of increased phosphorylated STAT3, and hence abnormal tumor proliferation, angiogenesis, invasion, and metastasis. This evidence concerns the gene STAT3 and neoplasm.